Background: The incidence of esophageal adenocarcinoma has risen dramatically over the past half century, and the underlying reasons are incompletely understood. Broad shifts to the upper gastrointestinal microbiome may be partly responsible. The goal of this study was to describe alterations in the esophageal microbiome that occur with progression from Barrett's esophagus to esophageal adenocarcinoma.
Methods: A case-control study was performed of patients with and without Barrett's esophagus who were scheduled to undergo upper endoscopy. Demographic, clinical, and dietary intake data were collected, and esophageal brushings were collected during the endoscopy. 16S rRNA gene sequencing was performed to characterize the microbiome.
Results: A total of 45 patients were enrolled and included in the analyses [16 controls; 14 Barrett's esophagus without dysplasia (NDBE); 6 low-grade dysplasia (LGD); 5 high-grade dysplasia (HGD); and 4 esophageal adenocarcinoma]. There was no difference in alpha diversity between non-Barrett's esophagus and Barrett's esophagus, but there was evidence of decreased diversity in patients with esophageal adenocarcinoma as assessed by Simpson index. There was an apparent shift in composition at the transition from LGD to HGD, and patients with HGD and esophageal adenocarcinoma had decreased Firmicutes and increased Proteobacteria. In addition, patients with HGD or esophageal adenocarcinoma had increased Enterobacteriaceae and Akkermansia muciniphila and reduced Veillonella. In the study population, patients taking proton pump inhibitors had increased Streptococcus and decreased Gram-negative bacteria overall.
Conclusions: Shifts in the Barrett's esophagus-associated microbiome were observed in patients with HGD and esophageal adenocarcinoma, with increases in certain potentially pathogenic bacteria.
Impact: The microbiome may play a role in esophageal carcinogenesis.
©2019 American Association for Cancer Research.
Conflict of interest statement
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.Dis Esophagus. 2017 Mar 1;30(3):1-5. doi: 10.1093/dote/dow025. Dis Esophagus. 2017. PMID: 28184470 Free PMC article.
A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):240-248. doi: 10.1158/1055-9965.EPI-16-0640. Epub 2016 Oct 11. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 27729357 Free PMC article. Clinical Trial.
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.Gastroenterology. 2013 Sep;145(3):548-53.e1. doi: 10.1053/j.gastro.2013.05.040. Epub 2013 May 25. Gastroenterology. 2013. PMID: 23714382 Clinical Trial.
Controversies in Barrett's esophagus: management of high grade dysplasia.Semin Gastrointest Dis. 2001 Jan;12(1):26-32. Semin Gastrointest Dis. 2001. PMID: 11215852 Review.
Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.World J Gastroenterol. 2019 May 14;25(18):2149-2161. doi: 10.3748/wjg.v25.i18.2149. World J Gastroenterol. 2019. PMID: 31143067 Free PMC article. Review.
Cited by 1 article
Exploring Esophageal Microbiomes in Esophageal Diseases: A Systematic Review.J Neurogastroenterol Motil. 2020 Apr 30;26(2):171-179. doi: 10.5056/jnm19240. J Neurogastroenterol Motil. 2020. PMID: 32235026 Free PMC article. Review.